Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Succimer, an oral lead chelator.

K V Mann1, J D Travers

  • 1Medical Affairs, McNeil Consumer Products Company, Fort Washington, PA 19034.

Clinical Pharmacy
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obstetric and gynecologic ultrasound curriculum and competency assessment in residency training programs: consensus report.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2018
Same author

Barriers to prevention: physician perceptions of ideal versus actual practices in reducing cardiovascular risk.

Canadian family physician Medecin de famille canadien·2011
Same author

Interprofessional education for students of the health professions: the "Seamless Care" model.

Journal of interprofessional care·2009
Same author

Linking assessment to learning: a new route to quality assurance in medical practice.

Medical education·2002
Same author

Using standardized patients to identify students needing extra training in interviewing skills.

Academic medicine : journal of the Association of American Medical Colleges·2001
Same author

Community family medicine teachers' perceptions of their teaching role.

Medical education·2001

Succimer effectively reduces lead levels in children with lead poisoning by forming stable complexes with lead and increasing its urinary excretion. This oral chelating agent offers a promising treatment option, though multiple courses may be needed to prevent lead rebound.

Area of Science:

  • Toxicology
  • Pharmacology
  • Environmental Health

Background:

  • Lead poisoning poses significant health risks, particularly in children.
  • Heavy metal chelation therapy is crucial for managing lead toxicity.
  • Succimer is an orally active chelating agent for heavy metal poisoning.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of succimer for lead poisoning treatment.
  • To evaluate succimer's role in managing lead toxicity in pediatric patients.
  • To assess the dosage and administration guidelines for succimer therapy.

Main Methods:

  • Review of existing literature on succimer's use in lead poisoning.
  • Analysis of clinical trial data regarding efficacy and adverse effects.

Related Experiment Videos

  • Examination of succimer's mechanism of action in chelating lead and other heavy metals.

    • Main Results:

    • Succimer forms stable complexes with lead, increasing urinary lead excretion.
    • It reverses lead's adverse effects on heme synthesis without depleting essential minerals.
    • Common side effects include gastrointestinal issues; drug interactions are minimal.
    • Effective in lowering blood lead concentrations, especially in children with levels >45 µg/dL.

    Conclusions:

    • Succimer is an effective oral chelator for lead poisoning, particularly in pediatric cases.
    • It demonstrates selectivity for lead and reverses toxic metabolic effects.
    • Potential for lead rebound necessitates consideration of multiple treatment courses.